AZTR Azitra, Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 1701478 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-98.9%
TTM net income YoY20.5%
TTM EPS YoY71.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-146,468.5%
Net margin-119,566.6%
FCF margin-135,885.3%
EBITDA margin-144,793.5%
Returns
ROE-208.3%
ROA-143.8%
ROIC (approx.)-767.7%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets22.6%
Debt / equity0.00x
Current ratio3.80x
Interest coverage-903.38x
Cash quality & payout
Operating cash flow / net income1.14x
Accruals ratio19.5%
Payout ratio—
Capex / revenue114.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0 | $7,500 | $686,000 | $284,000 |
| R&D expense | $4.84M | $4.72M | $3.64M | $6.10M |
| SG&A expense | $6.13M | $6.27M | $4.49M | $3.64M |
| Operating income | -$10.97M | -$10.99M | -$7.45M | -$9.45M |
| Interest expense | $7,587 | $12,160 | $167,726 | $251,891 |
| Pretax income | -$10.95M | -$8.96M | -$11.27M | -$10.68M |
| Income tax | $8,319 | $9,031 | $17,308 | — |
| Net income | -$10.96M | -$8.97M | -$11.28M | -$10.68M |
| EBITDA | -$10.83M | -$10.85M | -$7.32M | -$9.33M |
| EPS (basic) | -2.25 | -15.70 | -54.98 | -12.74 |
| EPS (diluted) | -2.25 | -15.70 | -54.98 | -12.74 |
| Weighted avg. shares (diluted) | 4.87M | 571,162 | 229,866 | 1.06M |
| Balance sheet | ||||
| Cash & equivalents | $2.07M | $4.55M | $1.80M | $3.49M |
| Receivables | $912 | $233 | — | $175,000 |
| Current assets | $3.02M | $5.23M | $2.54M | $4.14M |
| PP&E, net | $548,591 | $653,957 | $710,075 | $846,958 |
| Intangibles | $316,673 | $246,420 | $210,881 | $219,567 |
| Total assets | $5.03M | $7.36M | $5.12M | $7.17M |
| Current liabilities | $1.07M | $1.38M | $1.60M | $2.22M |
| Total liabilities | $1.22M | $1.66M | $2.20M | $9.73M |
| Shareholders' equity | $3.80M | $5.70M | $2.91M | -$36.26M |
| Shares outstanding | 1.07M | 1.15M | 403,246 | 1.04M |
| Cash flow statement | ||||
| Operating cash flow | -$11.22M | -$10.18M | -$7.36M | -$8.35M |
| Capital expenditure | $24,213 | $8,569 | $26,544 | $33,101 |
| Free cash flow | -$11.25M | -$10.19M | -$7.39M | -$8.38M |
| Investing cash flow | -$182,909 | -$379,246 | -$318,259 | -$336,761 |
| Financing cash flow | $8.92M | $13.32M | $5.98M | $4.13M |
| Depreciation & amortization | $138,069 | $131,188 | $129,653 | $125,885 |
| Stock-based compensation | $62,744 | $245,053 | $151,505 | $184,465 |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.